Myocardial Viability Assessment Before Surgical Revascularization in Ischemic Cardiomyopathy: JACC Review Topic of the Week

J Am Coll Cardiol. 2021 Sep 7;78(10):1068-1077. doi: 10.1016/j.jacc.2021.07.004.

Abstract

Ischemic cardiomyopathy results from the combination of scar with fibrosis replacement and areas of dysfunctional but viable myocardium that may improve contractile function with revascularization. Observational studies reported that only patients with substantial amounts of myocardial viability had better outcomes following surgical revascularization. Accordingly, dedicated noninvasive techniques have evolved to quantify viable myocardium with the objective of selecting patients for this form of therapeutic intervention. However, prospective trials have not confirmed the interaction between myocardial viability and the treatment effect of revascularization. Furthermore, recent observations indicate that recovery of left ventricular function is not the principal mechanism by which surgical revascularization improves prognosis. In this paper, the authors describe a more contemporary application of viability testing that is founded on the alternative concept that the main goal of surgical revascularization is to prevent further damage by protecting the residual viable myocardium from subsequent acute coronary events.

Keywords: coronary artery disease; heart failure; ischemic cardiomyopathy; left ventricular function; myocardial viability.

Publication types

  • Review

MeSH terms

  • Cardiomyopathies / physiopathology*
  • Cardiomyopathies / surgery
  • Humans
  • Myocardial Ischemia / physiopathology*
  • Myocardial Ischemia / surgery
  • Myocardial Revascularization*
  • Myocardium*
  • Tissue Survival*
  • Ventricular Function, Left